---
title: "Repatha (evolocumab), all indications: Safety questions"
description: "Safety questions on Repatha (evolocumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Monitoring, Warnings, and Side effects. Questions: When should LDL cholesterol be checked after starting Repatha? Does Repatha contain latex? Can Repatha cause allergic reactions or angioedema? What side effects have been reported with Repatha after approval? 3 further questions follow. 7 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/repatha/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Repatha (evolocumab), all indications: Safety questions

Manufacturer: Amgen Inc.  
Prescribing information: [Repatha](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf)  
Indication pages: [Cardiovascular event risk reduction](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction)

## Monitoring

<a id="repatha-ldl-monitoring"></a>

### When should LDL cholesterol be checked after starting Repatha?

> “Assess LDL-C when clinically appropriate. The LDL-lowering effect of REPATHA may be 
> measured as early as 4 weeks after initiation. 
> • 
> When monitoring LDL-C for patients receiving REPATHA 420 mg once monthly, note that 
> LDL-C can vary during the dosing interval in some patients; recommend measuring LDL-C just 
> prior to the next scheduled dose [see Clinical Studies (14)].”

Source: [REPATHA: Prescribing information, page 2, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=2)

## Warnings

<a id="repatha-latex"></a>

### Does Repatha contain latex?

> “The prefilled single-dose SureClick<sup>®</sup> autoinjector and prefilled single-dose syringe presentations of 
> REPATHA that contain dry natural rubber (a derivative of latex) in the needle cover may cause an 
> allergic reaction in individuals sensitive to latex. Instruct patients to inform their healthcare provider if 
> they are sensitive to latex. Consider prescribing a presentation of REPATHA that does not contain dry 
> natural rubber for individuals that are sensitive to latex [see How Supplied/Storage and Handling (16)].”

Source: [REPATHA: Prescribing information, page 4, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=4)

> “The prefilled single-dose pen is not made with natural rubber latex.”

Source: [REPATHA: Prescribing information, page 27, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=27)

> “Not Made with Natural Rubber Latex – 
> Strength 
> Packaging Unit 
> NDC 
> 140 mg/mL prefilled single-dose pen 
> Carton of 2 
> 72511-143-02 
> 140 mg/mL prefilled single-dose pen 
> Carton of 1 
> 72511-143-01 
> 140 mg/mL prefilled single-dose SureClick<sup>®</sup> autoinjector  
> Carton of 2 
> 72511-393-02 
> 140 mg/mL prefilled single-dose SureClick<sup>®</sup> autoinjector  
> Carton of 1 
> 72511-393-01”

Source: [REPATHA: Prescribing information, page 26, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=26)

Note: The last passage is the start of the NDC table in section 16 of the Prescribing Information, which lists the pen and SureClick autoinjector cartons under "Not Made with Natural Rubber Latex"; the same table lists a SureClick autoinjector carton (72511-760-02) and a prefilled syringe carton (72511-750-01) under "Contains Dry Natural Rubber".

<a id="repatha-allergic-reactions"></a>

### Can Repatha cause allergic reactions or angioedema?

> “Hypersensitivity reactions, including angioedema, have been reported in patients treated with REPATHA. 
> If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with REPATHA, 
> treat according to the standard of care, and monitor until signs and symptoms resolve. REPATHA is 
> contraindicated in patients with a history of serious hypersensitivity reactions to evolocumab or any 
> excipient in REPATHA [see Contraindications (4)].”

Source: [REPATHA: Prescribing information, page 4, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=4)

> “Hypersensitivity reactions: Angioedema”

Source: [REPATHA: Prescribing information, page 8, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=8)

<a id="repatha-contraindications"></a>

### Who should not take Repatha (contraindications)?

> “REPATHA is contraindicated in patients with a history of a serious hypersensitivity reaction to 
> evolocumab or any of the excipients in REPATHA. Serious hypersensitivity reactions including 
> angioedema have occurred in patients treated with REPATHA [see Warnings and Precautions (5.1)].”

Source: [REPATHA: Prescribing information, page 3, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=3)

## Side effects

<a id="repatha-postmarketing"></a>

### What side effects have been reported with Repatha after approval?

> “The following additional adverse reactions have been identified during post-approval use of REPATHA. 
> Because these reactions are reported voluntarily from a population of uncertain size, it is not always 
> possible to reliably estimate their frequency or establish a causal relationship to drug exposure. 
>
> • 
> Hypersensitivity reactions: Angioedema 
> • 
> Influenza-like illness”

Source: [REPATHA: Prescribing information, page 8, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=8)

<a id="repatha-injection-site-reactions"></a>

### How common are Repatha injection site reactions in hypercholesterolemia trials?

> “The adverse reactions described below are from a pool of the 52-week trial and seven 12-week trials. The 
> mean and median exposure durations of REPATHA in this pool of eight trials were 20 weeks and 
> 12 weeks, respectively.”

Source: [REPATHA: Prescribing information, page 6, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=6)

> “Injection site reactions occurred in 3.2% and 3.0% of REPATHA-treated and placebo-treated patients, 
> respectively. The most common injection site reactions were erythema, pain, and bruising. The 
> proportions of patients who discontinued treatment due to local injection site reactions in 
> REPATHA-treated patients and placebo-treated patients were 0.1% and 0%, respectively.”

Source: [REPATHA: Prescribing information, page 6, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=6)

Note: These rates come from placebo-controlled trials in adults with hypercholesterolemia. The Prescribing Information gives no separate injection site reaction rate for the cardiovascular outcomes trials and states that the FOURIER safety profile was generally consistent with these trials.

<a id="repatha-antibodies"></a>

### Do patients develop antibodies to Repatha?

> “In a pool of placebo- and active-controlled clinical trials, 0.3% (48 out of 17,992) of adult patients treated 
> with at least one dose of REPATHA tested positive for the development of binding antibodies”

Source: [REPATHA: Prescribing information, page 11, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=11)

> “Patients whose sera tested positive for binding antibodies were further evaluated 
> for neutralizing antibodies; none of the patients tested positive for neutralizing antibodies.”

Source: [REPATHA: Prescribing information, page 12, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=12)

> “There was no evidence that the presence of anti-drug binding antibodies impacted the pharmacokinetic 
> profile, clinical response, or safety of REPATHA.”

Source: [REPATHA: Prescribing information, page 12, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=12)

## Related pages
- [Medical information: Repatha (evolocumab): All indications](https://www.evicenter.com/medical-information/repatha)
- [Indication](https://www.evicenter.com/medical-information/repatha/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/repatha/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/repatha/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/repatha/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/repatha/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/repatha/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/repatha/access-and-coverage)
